momelotinib

Details

Files

Generic Name:

momelotinib

Project Status:

Active

Therapeutic Area:

Myelofibrosis

Manufacturer:

GlaxoSmithKline Inc.

Call for patient/clinician input open:

May 9, 2024

Brand Name:

TBC

Project Line:

Reimbursement Review

Project Number:

PC0355-000

Call for patient/clinician input closed:

June 28, 2024

Tumour Type:

Other

NOC Status at Filing:

Pre NOC

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

Momelotinib is indicated for the treatment of disease-related splenomegaly or symptoms, and anemia in adult patients with primary myelofibrosis, post polycythemia vera myelofibrosis or post essential thrombocythemia myelofibrosis who are Janus Kinase (JAK) inhibitor naïve or have been treated with a JAK inhibitor.

Submission Type:

Initial

Fee Schedule:

Schedule A

Indications:

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	May 09, 2024
Call for patient/clinician input closed	June 28, 2024
Submission received	June 19, 2024
Submission accepted	-
Draft CADTH review report(s) provided to sponsor for comment	September 19, 2024
Deadline for sponsors comments	October 01, 2024
CADTH review report(s) and responses to comments provided to sponsor	October 31, 2024
Expert committee meeting (initial)	November 13, 2024
Draft recommendation issued to sponsor	November 25, 2024 To November 27, 2024
Draft recommendation posted for stakeholder feedback	December 05, 2024
End of feedback period	December 19, 2024

Files

Patient and Clinician Group input View PDF

Last Updated : July 10, 2024